Abstract
Follicular thyroid cancer is a slow-progressing cancer with better prognosis than other types of thyroid cancer. However, treatment for metastatic cancer is very difficult. We treated 11 patients of advanced follicular thyroid cancer with multiple metastases with stereotactic body radiotherapy using the CyberKnife. Of the total 83 lesions that we treated, 53 had complete remission (64%), 28 had partial remission (34%), and two had progressive disease (2%). The complications were minimal. For those patients not indicated for chemotherapy, multisession CyberKnife radiosurgery is a viable option for the treatment of post-surgery recurrent or metastatic follicular thyroid cancer.
Highlights
Follicular thyroid cancer is classified as differentiated thyroid cancer, which progresses relatively slowly with better prognosis compared to undifferentiated thyroid carcinoma
CyberKnife, but she had no complication of stereotactic body radiotherapy (SBRT) for six months before the chemotherapy
Our research focused on follicular carcinoma which is rare and more invasive and metastatic compared to papillary carcinoma
Summary
Follicular thyroid cancer is classified as differentiated thyroid cancer, which progresses relatively slowly with better prognosis compared to undifferentiated thyroid carcinoma. Overall five-year survival rates for papillary thyroid carcinoma, follicular thyroid carcinoma, medullary thyroid cancer, and anaplastic thyroid cancer are near 100%, 97%, 90%, and 7%, respectively [1]. Distant metastases occur in patients with differentiated thyroid carcinoma with a prevalence of up to 10%. The aim of treatment is to eradicate cancer and to minimize treatment-related morbidity. The first choice of treatment is surgery which is difficult for metastatic lesions. CyberKnife radiosurgery is less invasive compared to standard surgery, and thereby is more suitable for the elderly patients. Recurrence and metastatic lesions can be expected to be controlled by CyberKnife with minimal complications
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call